Patients with a rare and aggressive form of liposarcoma need treatment advances

Dedifferentiated liposarcoma, or DDLPS, is a rare and aggressive form of sarcoma with a poor prognosis. Patients impacted by this cancer have had no significant changes to standard of care with first-line treatment options in 45 years.

In May 2022, the first patient was enrolled at UZ Leuven (Belgium) by Patrick Schöffski’s team in our clinical trial called Brightline-1 (ClinicalTrials.gov Identifier: NCT05218499), a Phase II/III, randomized, open-label, multi-center study, investigating brigimadlin (BI 907828) compared to doxorubicin as a first-line treatment for patients with advanced DDLPS. Approximately 390 patients are planned to be enrolled in the study globally with sites across Europe, North America (approximately 25 study sites in the U.S.) and Asia. This compound is an investigational agent and has not been approved for use by any regulatory authority including the U.S. Food and Drug Administration (FDA). The efficacy and safety of this investigational compound have not been established.

For U.S. healthcare professionals or investigators interested in learning more, visit: http://hcp.brightline-trial.com/

Through this trial evaluating brigimadlin, and in partnership with experts in this field, we intend to expand our knowledge, and that of the medical community, of cancer development.

Our goal is to transform the lives of people with cancer by delivering medical innovations in areas of high unmet need. Boehringer Ingelheim is committed to pioneering treatment advancements in some of the most challenging and most impactful areas of cancer.

Our rich pipeline of next-generation oncology treatments is comprised of cancer cell-directed and immuno-oncology therapies, the smart combinations of which may hold the greatest benefit for most patients. We proactively collaborate with patients, advocacy organizations, and the world’s leading academic centers and industry, because we believe together, we can make a bigger impact in transforming the lives of people with cancer.

We hope the results of this clinical trial will provide sarcoma specialists with more therapeutic options that may ultimately improve the lives of patients with DDLPS.

The Sarcoma Alliance recognizes the importance of clinical trials and is excited about the prospects of Boehringer Ingelheim's clinical trial for dedifferentiated liposarcoma (DDLPS).  The sarcoma community is grateful for the company’s efforts and persistence with clinical trials for this rare disease.  We are hopeful that the trials will yield a successful, long overdue, new treatment option for DDLPS patients." Jennifer Nellany, Board Chair of Sarcoma Alliance 

https://sarcomaalliance.org/clinical-trials

The Sarcoma Alliance is an international non-profit advocacy organization focusing on education, support, and guidance for people affected by sarcoma, including patients, family members, and caregivers.

Latest clinical trial progress as of 2023:

In Q2 2023, the Brightline-1 clinical trial program transitioned to Phase III. This milestone is a promising step towards delivering meaningful advances for the treatment of this rare and aggressive form of sarcoma.

Date published: 25 May 2022, updated September 2023

MPR-US-102729